On March 18, 2026, Frost & Sullivan (Frost & Sullivan, abbreviated as "Frost & Sullivan") and Forbes China successfully co-hosted the "2026 Forbes China Pioneer Innovators in Industry Development Selection Gala Banquet" at the Shanghai Waldorf Astoria Hotel. At this event, a total of 24 industry-leading enterprises, 8 outstanding experts and entrepreneurs, as well as 3 innovative brands were honored to be selected. These outstanding individuals and enterprises, with their exceptional innovation capabilities and relentless spirit of exploration, jointly demonstrated the vibrant vitality and development potential of China's healthcare industry, drawing a magnificent blueprint full of hope and vitality for the future of the industry.
Advantages of the 2026 Forbes China Industry Development Pioneer Selection
The 2026 Forbes China Industry Development Pioneer Awards aim to pay tribute to those business leaders who have blazed new trails in technology and reshaped market landscapes with their extraordinary innovative spirit and outstanding leadership. We look forward to taking this opportunity to gather pioneering forces, jointly drive the industry forward, empower industrial innovation, and inject strong momentum into the sustainable development of society.
1. Building Global Brand Power
This selection combines the brand momentum of Forbes with the industry depth of Frost & Sullivan, providing award-winning companies with a value uplift from 'industry recognition' to 'global brand'. Unlike mere exposure through communication or capital endorsement, with the support of Forbes' brand credibility, companies can establish a higher level of recognition and trust in the international market, achieving a critical leap from 'product output' to 'brand output'.
Empowering the Internationalization Strategy
Participating in the Forbes China Industry Development Pioneer Selection is not only an international recognition of an individual or company's innovation and leadership, but also allows enterprises to leverage Frost & Sullivan's extensive presence in developed and emerging markets, its industry insights with an international perspective, and its deep linkage with the global capital network. This helps companies accurately showcase their core strengths, efficiently expand overseas opportunities, and comprehensively enhance their international visibility.
3. Enhancement of corporate investment value
Against the backdrop of the current healthcare industry capital's high focus on innovation and value, this selection provides highly valuable third-party authoritative recognition for the winning enterprises. Participating in the Pioneer Awards jointly initiated by Frost & Sullivan and Forbes helps to demonstrate the core competitiveness of enterprises in terms of technical strength, business model, and growth potential to investment institutions, industrial capital, and the secondary market. It further enhances the attractiveness of enterprises to capital and wins more market opportunities for subsequent market expansion.
4. Precise placement across global media channels
Relying on the strong communication resource matrix built by Forbes China and Frost & Sullivan China, which includes the Forbes China official website, official WeChat account, magazine, as well as the official website of Frost & Sullivan China and global distribution channels and official WeChat account platforms, the service comprehensively covers top domestic and international media, reaching hundreds of millions of audiences. At the same time, by integrating multiple communication channels such as media, funds, banks, and securities firms, both parties can achieve precise and efficient promotion deployments. The selection results and the stories of the winners will receive high-frequency and high-quality exposure in mainstream domestic and international media, effectively enhancing the industry awareness and reputation of leading healthcare enterprises and innovators, truly transforming the potential of honor into brand value and market influence.
Overview of Award-winning Enterprises
The 2026 Forbes China Industry Development Pioneer Awards Ceremony and the 2026 New Era Brand Development Forum
The 2026 Forbes China Industry Development Leaders Awards Ceremony and the 2026 New Era Brand Development Forum invited guests such as Aroop Zutshi, Global President and Managing Partner of Frost & Sullivan, Dr. Wang Xin, Global Partner of Frost & Sullivan, Co-Chairman of the Asia-Pacific Region and Chairman of China, Zhang Guohua, President of the Chinese Advertising Association, Global Vice-President of the International Advertising Association and Chairman of the Council of the National Advertising Research Institute, Graham Earnshaw, Chief Strategy Officer of the Forbes China Group, and Professor Wang Yu, President of the China Hepatitis Prevention and Control Foundation, to attend and speak.
2026 Forbes China's Leading Companies in Industry Development (Winning Enterprises in the Healthcare Field)
Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan China, and Guo Junyi, General Manager of Business Operations for Forbes China Group, presented awards on behalf of Ausbio (Nantong) Biotechnology Co., Ltd.
Aoskang Biotechnology (Nantong) Co., Ltd., as a leading enterprise focusing on providing large-scale, compliant production solutions for biopharmaceuticals, is committed to efficiently promoting the transformation process of biopharmaceutical research and development through its comprehensive cell culture medium + CRDMO service system, benefiting patients around the world.
Beijing Gene Qiming Biotechnology Co., Ltd. is a leading enterprise in the field of iNKT cell cultivation and treatment. After 10 years of effort, it has built a biomedical and immunological basic research team of over a hundred people; it has established the largest iNKT cell basic research platform and the largest pilot production platform in China; it has been recognized as a national high-tech enterprise, a Beijing "specialized, refined, characteristic and innovative" enterprise, a Beijing new technology, new product and new service enterprise, and a leading enterprise in the cell industry of Zhongguancun Biomedical Base. It has obtained multiple national and international invention patents. The company ranks first globally in terms of iNKT cell product categories, the number of national registered clinical trial indications, and clinical progress, achieving China's "leader" position in the global iNKT cell treatment field.
Beijing Likang Life Technology Co., Ltd., as a leader in the field of tumor precision immunotherapy, focuses on the development and application of cutting-edge biotechnology. By integrating advanced scientific research resources and industrialization capabilities, the company is committed to providing innovative solutions for the health industry, demonstrating its deep layout and leadership in the field of biotechnology.
Boya Life is a leading enterprise focusing on cell technology, providing personalized cell therapy solutions as a whole. From 2009 to 2026, after 17 years of in-depth development, Boya Life has established a new cell industry chain integrating 'cell automated medical devices - life bank - cell new drug research and industrialization' in the field of cell biomedicine. It is also the first domestic innovative enterprise to extend cell technology from the human health field to the animal health field, comprehensively promoting the upgrading of livestock breeding and propagation, animal cloning, and regenerative medicine technologies.
Bosugene Pharma Technology (Suzhou) Co., Ltd. is a leading enterprise dedicated to the research and development and industrialization of breakthrough cell therapy technologies. The company has deeply cultivated major indications such as tumors and autoimmune diseases. It has established multiple core technology platforms including fully automated autologous CAR-T, GUIDED in vivo CAR-T, eUCAR-γδT universal types, and MNanoNET NKCE, constructing a full-chain industrial system covering R&D, production, and clinical practice. Upholding the belief of "Bosoming Love to the World, Blessing the Living," the company is committed to developing innovative drugs that benefit patients, continuously launching internationally leading First-in-class and Best-in-class cell therapies to benefit a large number of cancer and autoimmune disease patients.
Fangtuo Biotech is a leading enterprise focusing on rAAV gene therapy, having successfully established a differentiated and competitive product pipeline covering three major therapeutic areas: ophthalmology, cardiovascular, and nervous system. It provides patients with rare diseases and chronic conditions with one-time and long-term effective solutions. The company's multiple products have the potential to be among the best globally. It is one of the few biotech companies in the world with integrated capabilities from early drug discovery, CMC development to clinical trial research. The company is committed to developing innovative, safe, effective, and affordable gene therapy drugs for patients worldwide, meeting the vast unmet clinical medical needs.
As a leading enterprise focusing on the research and development of active collagen, Fiman Biotechnology has over 20 years of rich experience in biological extraction, pharmaceutical research and purification, R&D innovation, and quality systems. Relying on a medical-grade cattle farm built according to EU standards, a collagen intelligent factory certified with the ISO13485 quality system, and more than 50 exclusive patented technologies, it has constructed an industry-leading full-link R&D and production platform from raw materials to end products.
Hangzhou Aomai Pharmaceutical Co., Ltd. is a leading enterprise dedicated to the research and development of original innovative drugs. Established in 2000, Aomai Pharmaceutical is a national high-tech enterprise focusing on the innovative research and development of small molecule drugs urgently needed in clinical practice. The company revolves around unmet clinical needs, concentrating on key areas such as anesthesia, cardiovascular and cerebrovascular diseases, and nervous system diseases, continuously advancing the research and development of globally competitive innovative drugs.
Henan Real Biotechnology Co., Ltd. is a leading enterprise focusing on innovative drugs for treating viral infections, tumors, and cardiovascular and cerebrovascular diseases. The company's mission is to improve human health through genuine innovation, especially in the fields of antiviral and anti-tumor therapies, by exploring and solving drug resistance issues in existing treatment regimens. The company aims to find newer and better treatment options to address unmet clinical needs.
Jehua Biotechnology (Qingdao) Co., Ltd., as a leading enterprise in the field of broad-spectrum macromolecular antiviral drugs, relies on its profound foundation in basic research and the development of new biological drugs over the past two decades. It has established a complete biopharmaceutical technology chain from laboratory construction of new macromolecular proteins to large-scale industrial production, and has the capability to continuously innovate and produce high-value original biological drugs.
Kangde (Shenzhen) Biotechnology Co., Ltd. is a leading enterprise that has attracted significant attention in the field of precision prevention of malignant tumors. Relying on its independently constructed miRNA molecular technology platform and AI-powered system, the company focuses on early detection and full-cycle management of characteristic cancer types. It is committed to improving the survival rate of cancer types that currently have no effective solutions through disruptive original technologies, making healthy longevity within reach.
Kangnuo Biopharmaceutical Co., Ltd. is a leading enterprise in the field of mitochondrial medicine. The company focuses on researching diseases caused by mitochondrial dysfunction and is committed to applying NAD+ in scientific research in areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging, providing scientific solutions to extend healthy lifespan.
As a leading enterprise in the field of small molecule targeted research and development, Lingke Pharmaceutical (Zhejiang) Co., Ltd. meets unmet clinical needs by developing innovative therapies. It strives to benefit patients worldwide with differentiated innovative therapies. To date, Lingke Pharmaceutical has developed several independently developed first-in-class clinical new drugs and has conducted multiple clinical trials globally either independently or in collaboration with international partners.
MaiRuike (Shenzhen) Biotechnology Co., Ltd. is a leading enterprise in the field of liquid biopsy and early disease screening technology innovation, focusing on microRNA and artificial intelligence technologies. It is committed to providing highly accurate and sensitive auxiliary diagnostic solutions for major diseases such as CNS disorders and tumors. Relying on its independently developed microRNA technology platform, the company has constructed a multi-modal early warning model of 'blood miRNA + digital biomarkers'. This model has achieved the deep integration of blood miRNA with digital biomarkers for the first time, enhancing the sensitivity, accuracy, and generalization ability of disease screening, reducing the risks of missed diagnosis and misjudgment, and is of great significance for optimizing the allocation of public health resources and managing the health risks of major diseases.
Shanghai Zhileng Medicine Technology Co., Ltd., as a leading enterprise in the field of innovative drug research and development for central nervous system diseases and liver diseases, is committed to meeting the urgent clinical needs of patients. The company has broken through core technical barriers and has achieved international leadership in clinical research projects, possessing global competitiveness.
TED Biologics (Zhejiang) Co., Ltd. (HKEX: 03880.HK) is a global CRDMO enterprise focusing on the fields of peptides and oligonucleotides. The company's predecessor, Zhongpei Biochemistry, was established in 2001 and has been deeply involved in the peptide field for twenty-five years. It has now developed into an integrated service platform covering the entire cycle from early discovery, clinical research to commercial production. Relying on its commercial production base in Hangzhou, China, and the ongoing expansion of its production capacity in the United States, TED Biologics has established delivery capabilities that meet the standards of major global regulatory agencies, serving pharmaceutical and biotechnology customers worldwide.
Jinxin Reproductive Medicine, as a leading enterprise in the field of assisted reproduction, focuses on providing integrated services for women's health throughout their life cycle and assisted reproduction. In recent years, relying on its cross-regional operational network and large-scale business foundation, Jinxin Reproductive Medicine has built a moat supported by 'deep technology, wide service coverage, and international standards,' demonstrating strong resilience and vitality in contributing to the construction of a fertility-friendly society.
Juitian Wisdom (Shenzhen) Co., Ltd. is a leading enterprise in the field of medical imaging innovation. The company has been deeply involved in micro-ultrasound equipment and has built a product matrix covering six major areas: primary healthcare, specialized diagnosis and treatment, therapy and rehabilitation, intelligent health, economic animal and pet healthcare. By precisely meeting the needs of diverse scenarios, it uses technological innovation to break through service links, empower human health management, assist in improving the quality and efficiency of the animal industry, and unleash the core value of industry upgrading and market expansion.
Shandong Huguo Stomatological Group Co., Ltd.
Shandong Hugu Oral Medical Group Co., Ltd. is a leading enterprise in the field of oral materials, providing a diversified product portfolio that includes oral clinical products, dental technician products, and digital oral products. Its comprehensive product matrix covers all scenarios for oral medical institutions (including hospitals and clinics) and dental laboratories, effectively meeting the diverse clinical needs of customers including restorers, implantologists, endodontists, orthodontists, and pediatric dentists.
Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan China, and Guo Junyi, General Manager of Business Operations for Forbes China Group, presented awards on behalf of Weimai Qingtong Medical Technology (Wuxi) Co., Ltd.
As a leading enterprise in the field of energy-based medical devices, Weima Qingtong Medical Technology (Wuxi) Co., Ltd. is the first medical device company in China to provide comprehensive minimally invasive and non-invasive energy medicine solutions. Its core radiofrequency anti-aging brand, YOUMAGIC Shuliti, is based on Tsinghua's energy technology, achieving multiple leaps in both treatment effectiveness and user comfort. The product has received dual certifications from the NMPA and FDA. The company is committed to becoming a leader in energy medicine in China and providing high-quality medical devices to more patients.
Health160 International Co., Ltd. is a leading enterprise in the field of comprehensive digital healthcare service platforms in China, dedicated to promoting the digital transformation of the healthcare industry through technological innovation. The company's core business is operating an online healthcare service platform—Health160. This platform effectively integrates online and offline resources, constructing a closed-loop ecosystem that connects medical institutions, healthcare professionals, and the general public. As a connector and enabler in the industry, the company has established a significant resource network advantage.
Shanghai Yuanhe Hospital Management Co., Ltd. is a leading enterprise in the field of medical health management. Yuanhe is committed to integrating high-quality medical resources under different mechanisms to build a remarkable international and domestic medical network; centered around a managed medical service system and driven by ultimate health outcomes, it provides comprehensive health and disease management services integrating prevention, diagnosis, and rehabilitation, creating a medical service experience that exceeds customer expectations. It also innovatively finances medical health services through insurance, breaking through the single logic of disease medical payment benefits. It has pioneered an innovative business model driven by three aspects: medical services + digital medicine + insurance finance.
Tianjin TEDA Biomedical Engineering Co., Ltd. is a leading enterprise in AI medical large models and MaaS services. With the core concept of 'technology innovation driving industrial upgrading', the company has formed a business pattern driven by both 'artificial intelligence + healthcare'. Relying on the high-quality resources of Peking University and Shenzhen Institute of Computing Science, it has introduced AI and big data technologies, deeply cultivated cutting-edge fields such as intelligent analysis of health data, precision medical algorithms, and medical image recognition. It has built a city-level 'token factory' and created a model of 'new quality productivity' in the healthcare field.
Xikangyun Hospital (9686.HK) is the creator and promoter of the urban cloud hospital platform model in China. The company uses the urban cloud hospital platform as a carrier, with its business divided into three major sectors: medical services, nursing services, and health management services. Among them, the home-based nursing network covers the whole country and serves 200 million people, empowering healthcare with technology and making high-quality medical care services accessible.
2026 Forbes China Industry Development Leaders (Winning Enterprises in the Healthcare Field)
Mao Hua, Senior Partner and Managing Director of Frost & Sullivan China, and Guo Junyi, General Manager of Business Operations at Forbes China Group, presented awards to Chen Li, Founder and CEO of Beijing Liko Life Technology Co., Ltd.
Dr. Chen Li, founder and CEO of Lika Life Sciences, holds a Ph.D. from the Institute of Biophysics, Chinese Academy of Sciences. He founded Lika Life Sciences in 2017, dedicated to developing precision immunotherapy drugs for tumors. He is a key innovator in China who developed the first AI+ tumor personalized antigen mRNA vaccine to enter clinical trials and achieve technology transfer.
Under the leadership of Chairman Mr. Ding Wei, San Biotech has completed a disruptive innovation in ergotamine production technology, achieving high-purity and large-scale production of ergotamine and continuously expanding its application boundaries. The company's ergotamine raw materials, oral capsules, and 'Bo Miao Yan' skincare products have all gained wide market recognition. With over two decades of experience in brand establishment and management in the Chinese market, including being a senior vice president and president of A.O. Smith Group's China company, CEO of Hengjie Group, and a Forbes China & Jiangsu Business Administration Influential Figure for 2025, the company has been involved in the establishment of 'zero-to-hundred-billion' brands.
Dou Liu, Ph.D., from University College London (UCL), is a high-level overseas talent in Shenzhen, with a senior professional title. He is a member of the British Pharmacists' Association and the American Pharmacists' Association, and is also a member of the European UNGAP research organization. Currently, he serves as the Chairman and CEO of Shenzhen Aoli Biotechnology Co., Ltd. with over 10 years of experience in pharmaceutical research. He has published international SCI core journals and international invention patents, including those in Pharmaceutics and European Journal of Pharmaceutical Science. He has been invited to participate in the American National Pharmaceutical Congress and the British National Pharmaceutical Congress multiple times and has given presentations.
Mao Hua, Senior Partner and Managing Director of Frost & Sullivan China, and Guo Junyi, General Manager of Business Operations for Forbes China Group, presented awards to Liu Longbin, Founder and CEO of Jiehua Biotechnology (Qingdao) Co., Ltd.
Mr. Liu Longbin is the founder, CEO, and Chief Scientist of Jiehua Biology, overseeing R&D, production, operations, and finance comprehensively. He leads the strategic layout and development direction, and is a composite leader in the biotechnology industry with both scientific research depth and business vision. As of 2024, his innovative industrial technology for high-expression TNK-tPA protein in CHO cells and circulatory perfusion is still the core technology source for the only two domestic companies developing new biologics for ischemic stroke. The clinical research results of this drug were published in the New England Journal of Medicine (NEJM), rewriting the rules for stroke treatment.
Liu Yarong, founder, chairman, and CEO of Shuli Bio, holds a Ph.D. from the University of Southern California in the United States. She has over a decade of experience in cell and gene therapy research and industrialization, having worked at multinational pharmaceutical companies such as Amgen. After returning to China, she led the development of the first batch of CAR-T products in the country. In 2019, she founded Shuli Bio, focusing on overcoming the challenges of solid tumor treatment and leading the company in developing the first domestically approved TIL drug (GT101) for clinical trials.
Ma Hua, Senior Partner and Managing Director of Frost & Sullivan China, and Guo Junyi, Managing Director of Business Operations for Forbes China Group, presented awards to Sun Lin, Chairman of Siede DiKang (Shanghai) Medical Technology Co., Ltd.
Sun Lin, founder and chairman of Siede DiKang, has a background in Wall Street investment banking and dollar funds and is an international entrepreneur in the field of tissue engineering and regenerative medicine. She leads a top R&D team from China and the United States that has been deeply involved in the industry for over 50 years, focusing on the development of globally patented bio-synthetic tissue engineering repair materials. She leads multi-center clinical trials in China and the United States, with her core product being the only heavy-duty product in the same field approved by the US FDA and entering global markets. She is leading the company into "AI + regenerative medicine," aiming to provide more patients with efficient and economical regenerative therapies. The company was ranked first among global wound management solution providers in 2021.
Ma Hua, Senior Partner and Managing Director of Frost & Sullivan China, and Guo Junyi, Managing Director of Business Operations for Forbes China Group, presented awards to Wang Li, Chairman and CEO of Shanghai Yixin Medical Devices Co., Ltd.
Ms. Wang Li is the founder, chairman, and CEO of Shanghai Yixin Medical Devices Co., Ltd., with over 20 years of experience in the medical device field. She played an important role as initiator and promoter in the development of Yixin Medical, driving multiple initiatives in technological innovation and market expansion, and leading Yixin Medical from its initial research and development to commercialization. Wang Li was named a 2026 Forbes China Industry Development Pioneer in 2026. In addition, she serves as a member of the Central Medical and Health Special Committee of the Jiusan Society, Deputy Director of the Economic and Financial Professional Committee of the Shanghai Municipal Committee of the Jiusan Society, Director and Secretary-General of the Shanghai Youxin Charity Foundation.
Yin Qingfeng is currently the chairman and general manager of Famaisheng Medical, concurrently serving as the head of the transformation department at the Sichuan Key Laboratory of Pediatric Drugs. He is a member of the Frost & Sullivan New Productivity Expert Committee, a LP of Qianyuan Jinhai New Drug Innovation Fund, and serves as Deputy Director and Member of several national academic organizations such as the China Kidney Disease Big Data Application Innovation Alliance, the Precision Medicine Branch of the Chinese Association of Traditional Chinese Medicine, and the Clinical Research Evaluation Professional Committee of Traditional Chinese Medicine of the Chinese Pharmaceutical Association.
2026 Forbes China Industry Development Innovation Brands (Award-winning enterprises in the medical field)
Ma Hua and Guo Junyi, Senior Partner and Managing Director of Frost & Sullivan China, jointly presented awards to representatives of the 2026 Forbes China Industry Development Innovation Brands—Shanghai Angpu Biotechnology Co., Ltd., Sihet Gene (Beijing) Biotechnology Co., Ltd., and Weibo Health.
Shanghai Angpu Biotechnology Co., Ltd. is an innovative brand in induced pluripotent stem cell (iPSC) technology, building an "AI + cytology" dual-driven intelligent manufacturing platform with standardized cell products and high-quality data, creating an incubator for innovative drug pipelines. Relying on rich clinical resources and leading iPSC preparation and differentiation technology systems, it ensures reliable supply of cell products, compliant and traceable biological databases, and comprehensively serves pharmaceutical companies, CROs, AI pharmaceuticals, and research customers.
Sihet Gene (Beijing) Biotechnology Co., Ltd. is an innovative brand in clinical-stage single-stranded oligonucleotide (ASO) drug research and development, dedicated to developing breakthrough therapies for major clinical needs. As a national high-tech enterprise and specialized small and medium-sized enterprise, Sihet Gene has won multiple entrepreneurship and innovation awards. With its solid technical accumulation and clear pipeline layout, it is fully committed to promoting the development of China's nucleic acid drug industry.
Weibo is a leading social media innovation brand in China, dedicated to providing a convenient platform for the public to create, share, and discover content. As an important vertical operation area, Weibo Health has always been committed to becoming a bridge connecting professional healthcare with public health. Continuously strengthening the professional ecosystem, enabling health knowledge to reach hundreds of millions of users scientifically and effectively, and actively contributing to improving the national health literacy through practical actions, fulfilling corporate social responsibilities, is an active and important driving force in the process of building Healthy China.
More exciting moments
